ライフサイエンスコーパス: nerve sheath tumor

1 3 for angiosarcoma and malignant peripheral-nerve sheath tumor).

2 stinal hyperplasia, and malignant peripheral nerve sheath tumor.

3 R kinase inhibitors against these aggressive nerve sheath tumors.

4 ct downstream of Ras in malignant peripheral nerve sheath tumors.

5 erve sheath tumors, and malignant peripheral nerve sheath tumors.

6 S in patients undergoing resection of spinal nerve sheath tumors.

7 affin-embedded specimens of human peripheral nerve sheath tumors.

8 annomas of patients with multiple peripheral nerve sheath tumors.

9 -catenin/CTNNA3 in the biology of peripheral nerve sheath tumors.

10 ysplasia, scoliosis and malignant peripheral nerve sheath tumors.

11 tion between benign and malignant peripheral nerve sheath tumors.

12 t advances in the diagnosis and treatment of nerve sheath tumors.

13 ) mutant fish developed malignant peripheral nerve sheath tumors.

14 ral ganglion-associated malignant peripheral nerve sheath tumors.

15 A total of 398 nerve sheath tumors (185 plexiform and 213 discrete tumo

16 2 unspecified type) and malignant peripheral nerve sheath tumor (2 of 14, 14%) were the most common n

17 rgo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma.

18 In malignant peripheral nerve sheath tumors and CNS tumors, the cancers traditio

19 way gliomas, as well as malignant peripheral nerve sheath tumors and glioblastomas.

20 eurofibromas as well as malignant peripheral nerve sheath tumors and other malignant tumors, are sign

21 characteristics of lipoma, benign peripheral nerve sheath tumor, and vascular malformation (n = 192)

22 characteristics of lipoma, benign peripheral nerve sheath tumor, and vascular malformation (n = 192)

23 fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma.

24 encompass schwannomas, neurofibromas, hybrid nerve sheath tumors, and malignant peripheral nerve shea

25 myxofibrosarcomas, and malignant peripheral nerve sheath tumors are characterized by complex genomic

26 ated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this review.

27 Spinal nerve sheath tumors are slow-growing neoplasms that aris

28 s are benign Schwann cell-derived peripheral nerve sheath tumors arising sporadically and within neur

29 mas, neurofibromas, and malignant peripheral nerve sheath tumors, as well as behavioral, cognitive, m

30 cluster in a distinct subgroup of peripheral nerve sheath tumors based on genome-wide DNA methylation

31 Patients diagnosed with spinal nerve sheath tumors between 2004 and 2017 were identifie

32 in the TME of cutaneous malignant peripheral nerve sheath tumor (C-MPNST) and spindle cell melanoma (

33 A novel classification scheme for peripheral nerve sheath tumors in murine models was therefore devis

34 Plexiform neurofibromas are peripheral nerve sheath tumors initiated by biallelic mutation of t

35 revealed that each of 3 malignant peripheral nerve sheath tumor (MPNST) cell lines from NF1 patients

36 /MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines.

37 een using NF1-deficient malignant peripheral nerve sheath tumor (MPNST) cells.

38 Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcom

39 Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcom

40 Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with

41 Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue

42 ved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication and managemen

43 ainst neuroblastoma and malignant peripheral nerve sheath tumor (MPNST) xenografts.

44 Malignant peripheral nerve sheath tumor (MPNST), a highly aggressive Schwann

45 s high predilection for malignant peripheral nerve sheath tumor (MPNST), a type of soft tissue sarcom

46 e is the development of malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sa

47 synovial sarcoma (SS), malignant peripheral nerve sheath tumor (MPNST), and undifferentiated pleomor

48 ients (15.1%) developed malignant peripheral nerve sheath tumor (MPNST), the most common neoplasms.

49 me risk of developing a malignant peripheral nerve sheath tumor (MPNST).

50 fibromatosis type 1 and malignant peripheral nerve sheath tumor (MPNST).

51 ty of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurofibromas.

52 Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue s

53 Malignant peripheral nerve sheath tumors (MPNST) are highly invasive soft tis

54 Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer tha

55 Malignant peripheral nerve sheath tumors (MPNST) develop in approximately 10%

56 ann cells in benign and malignant peripheral nerve sheath tumors (MPNST) from neurofibromatosis type

57 e epigenetic drivers of malignant peripheral nerve sheath tumors (MPNST) harboring loss-of-function p

58 rt cytotoxic effects in malignant peripheral nerve sheath tumors (MPNST) where estrogen is not involv

59 not been established in malignant peripheral nerve sheath tumors (MPNST) where NF1 mutations also occ

60 evaluation of HDACis in malignant peripheral nerve sheath tumors (MPNST), a class of highly aggressiv

61 that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of mortality.

62 comas, leiomyosarcomas, malignant peripheral nerve sheath tumors (MPNST), solitary fibrous tumors, sy

63 d molecular features of malignant peripheral nerve sheath tumors (MPNST).

64 enign neurofibromas and malignant peripheral nerve sheath tumors (MPNST).

65 altered in about 90% of malignant peripheral nerve sheath tumors (MPNST).

66 r lesions of aggressive malignant peripheral nerve sheath tumors (MPNST).

67 ng in neurofibromas and malignant peripheral nerve sheath tumors (MPNST).

68 ways in the majority of malignant peripheral nerve sheath tumors (MPNST).

69 lignant transformation (malignant peripheral nerve sheath tumor; MPNST), its neoplastic nature has be

70 oma cells isolated from malignant peripheral nerve sheath tumor (MPNSTs) of NPcis (Trp53(+/-) ; Nf1(+

71 We tested this in mouse malignant peripheral nerve sheath tumors (MPNSTs) and found that 18% of prima

72 ell cycle regulators in malignant peripheral nerve sheath tumors (MPNSTs) and neurofibromas (NFs).

73 erations in a series of malignant peripheral nerve sheath tumors (MPNSTs) and neurofibromas (NFs).

74 valent genetic event in malignant peripheral nerve sheath tumors (MPNSTs) and sporadically in other c

75 Malignant peripheral nerve sheath tumors (MPNSTs) are a type of rare sarcomas

76 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-re

77 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive neoplasms th

78 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and

79 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas wit

80 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive Schwann cell

81 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive tumors with

82 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, currently u

83 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, frequently

84 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive ca

85 Malignant peripheral nerve sheath tumors (MPNSTs) are chemotherapy resistant

86 Malignant peripheral nerve sheath tumors (MPNSTs) are devastating sarcomas fo

87 Malignant peripheral nerve sheath tumors (MPNSTs) are genetically diverse, ag

88 Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft

89 Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas of Schwann cel

90 Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas th

91 Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas th

92 NF1-associated malignant peripheral nerve sheath tumors (MPNSTs) are the major cause of mort

93 ly worse in primary RAS malignant peripheral nerve sheath tumors (MPNSTs) compared with unmatched spo

94 Malignant peripheral nerve sheath tumors (MPNSTs) develop sporadically or in

95 n cell lines from human malignant peripheral nerve sheath tumors (MPNSTs) driven by NF1 loss, HSF1 wa

96 ing, in differentiating malignant peripheral nerve sheath tumors (MPNSTs) from benign neurofibromas (

97 ann cells isolated from malignant peripheral nerve sheath tumors (MPNSTs) overexpress PDGF receptor-b

98 Malignant peripheral nerve sheath tumors (MPNSTs) represent a group of highly

99 Here we report that malignant peripheral nerve sheath tumors (MPNSTs) that arise in zebrafish as

100 e methylome analysis of malignant peripheral nerve sheath tumors (MPNSTs), benign neurofibromas, and

101 effective treatment for malignant peripheral nerve sheath tumors (MPNSTs), half of which result from

102 its lethal derivative, malignant peripheral nerve sheath tumors (MPNSTs), is thought to result in th

103 In malignant peripheral nerve sheath tumors (MPNSTs), Polycomb repressive comple

104 ach is being applied to malignant peripheral nerve sheath tumors (MPNSTs), rare Schwann cell-derived

105 al oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressiv

106 in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports a cooperati

107 ransformation of NFs to malignant peripheral nerve sheath tumors (MPNSTs).

108 human cancers, such as malignant peripheral nerve sheath tumors (MPNSTs).

109 le neoplasms, including malignant peripheral nerve sheath tumors (MPNSTs).

110 tial (ANNUBP) and/or to malignant peripheral nerve sheath tumors (MPNSTs).

111 et of which progress to malignant peripheral nerve sheath tumors (MPNSTs).

112 ntly progress to become malignant peripheral nerve sheath tumors (MPNSTs).

113 cell neoplasms known as malignant peripheral nerve sheath tumors (MPNSTs).

114 form spontaneously into malignant peripheral nerve sheath tumors (MPNSTs).

115 ased risk of developing malignant peripheral nerve sheath tumors (MPNSTs).These cancers are difficult

116 osarcomas (n = 27), one malignant peripheral-nerve sheath tumor (n = 7), 0 rhabdomyosarcoma (n = 2),

117 BACKGROUNDNeurofibroma/schwannoma hybrid nerve sheath tumors (N/S HNSTs) are neoplasms associated

118 ase are the development of benign peripheral nerve sheath tumors (neurofibromas), which can progress

119 ents develop Schwann cell lineage peripheral nerve sheath tumors (neurofibromas).

120 <.001), intramedullary tumors (P <.001), and nerve sheath tumors (NSTs) (P <.001).

121 Malignant peripheral nerve sheath tumors often arise in patients with neurofi

122 omocytoma, and two with malignant peripheral nerve sheath tumor (PNST) that arose in a ganglioneuroma

123 und to be comutated in high-grade peripheral nerve sheath tumors (PNST) in mice.

124 histologically resemble malignant peripheral nerve sheath tumors, rare neoplasms that occur in indivi

125 xiform neurofibromas to malignant peripheral nerve sheath tumors requires additional genetic changes,

126 of stay compared to open surgery for spinal nerve sheath tumor resection.

127 g degrees of C-->U RNA editing in peripheral nerve-sheath tumor samples (PNSTs) from patients with NF

128 l and plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in neurofibrom

129 Schwannomas are common peripheral nerve sheath tumors that can cause debilitating morbidit

130 raneural perineuriomas are benign peripheral nerve sheath tumors that cause progressive debilitating

131 Schwannomas are peripheral nerve sheath tumors that often occur in the setting of a

132 pathogenic pathways of malignant peripheral nerve sheath tumors, these mutant zebrafish lines provid

133 8 tumors spanning the spectrum of peripheral nerve sheath tumors to identify candidate drivers of MPN

134 n with schwannomatosis) in whom at least one nerve sheath tumor was reliably identified on MR images.

135 A total of 5,968 patients with spinal nerve sheath tumors were identified: 202 (3.4%) underwen

136 chondrosarcoma, and one malignant peripheral nerve sheath tumor) were analyzed.

137 romas, schwannomas, and malignant peripheral nerve sheath tumors, were presented.

138 TGF-beta receptor II in malignant peripheral nerve sheath tumors, which correspond to tumors in the N

139 which included one patient with a metastatic nerve sheath tumor who was stable for 9 months.

140 ype 1, which is characterized by disfiguring nerve sheath tumors with mast cell infiltration, increas